

RECEIVED

091-190390

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 SEP 17 PM 3:17	and 9 Copies	Expires:

Estimated average burden hours per response: 2.00

SEC / MR

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 19b-4(e)**

Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report**

SEC  
Mail Processing  
Section

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

NYSE Arca, Inc.

SEP 17 2015

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

Open-end Management Investment Company

Washington DC  
404

3. Class of New Derivative Securities Product:

Investment Company Units



15020574

4. Name of Underlying Instrument:

Dynamic Pharmaceutical Intellidex Index

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

Narrow-Based

6. Ticker Symbol(s) of New Derivative Securities Product:

PILL

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

NYSE, NASDAQ

8. Settlement Methodology of New Derivative Securities Product:

Regular way trades settle on T+3/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):

Not applicable.

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Martha Redding

Title:

Senior Counsel and Assistant Secretary

Telephone Number:

(212) 656-2938

Manual Signature of Official Responsible for Form:

September 16, 2015

Act Securities Exchange Act of 1934

Section 19b-4

Rule 19b-4(e)

Public Availability: SEP 17 2015

SEC 2449 (1/99)



SEP 17 PM 3:16  
SEP 17 2015

Martha Redding  
Senior Counsel  
Assistant Secretary

New York Stock Exchange  
11 Wall Street  
New York, NY 10005  
T + 1 212 656 2938  
F + 1 212 656 8101  
Martha.Redding@theice.com

SEC  
Mail Processing  
Section  
SEP 17 2015  
Washington DC  
404

Via Overnight Mail

September 16, 2015

Ms. Gail Jackson  
US Securities and Exchange Commission  
Division of Trading and Markets  
Station Place – Building I  
100 F Street, N.E. – Room 6628  
Washington, DC 20549

Re: 19b-4(e) – Transmittal


Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- Direxion Daily Cyber Security Bull 2X Shares (HAKK)**
- Direxion Daily Cyber Security Bear 2X Shares (HAKD)**
- Direxion Daily Pharmaceutical & Medical Bull 2X Shares (PILL)**
- Direxion Daily Pharmaceutical & Medical Bear 2X Shares (PILS)**
- ProShares MSCI Europe Dividend Growers ETF (EUDV)**
- SPDR MSCI International Real Estate Currency Hedged ETF (HREX)**
- SPDR S&P International Dividend Currency Hedged ETF (HDWX)**

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,

  
Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	SEP 17 2015